Patent and exclusivity expiry
26 products with a sourced exclusivity floor or recorded entrants. 11 lose a key patent or regulatory exclusivity between 2026 and 2030, and 10 already face launched biosimilars or generics. Bars end at the expiry year; markers are entrants. Filter by modality, company and region.
Floors, not forecasts
The patent year is the expiry of the key compound or composition patent as the marketing company discloses it, including supplementary protection certificates and patent term extensions where stated. Later formulation, method-of-use and manufacturing patents often extend practical exclusivity, and litigation or settlements can move entry earlier or later. Treat every bar as the earliest date competition could arrive, not the date it will.
Regulatory exclusivity is deterministic: 12 years from first US licensure for biologics (the Purple Book), 5 years for new chemical entities (the Orange Book), and 8 plus 2 years in the EU. It is the floor beneath the patent floor.
Why this matters
Loss of exclusivity is what turns a list price into a generic price and what forces the next generation of products to launch on time. The US paying-for-care and NHS pages show what each product costs today; this page says how long that lasts.
Add a product in src/data/exclusivity.ts with the 10-K, annual report or regulator page as the source. Products with no public disclosure are left out rather than guessed.